Diabetic Peripheral Neuropathic Pain Study

CNS Healthcare is conducting a phase II study for patients in the Orlando, Florida area with diabetic peripheral neuropathic pain. This study is designed to evaluate the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain.

Purpose:
This study is designed to evaluate the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain.

Eligibility:
Ages Eligible for Study:            18 to 70 Years
Genders Eligible for Study:      Both
Accepts Healthy Volunteers:    No

Inclusion Criteria:

- Orlando, Florida area residents only
- Male or female outpatients, 18 to 70 years of age
- A diagnosis of painful diabetic neuropathy
- Controlled blood glucose
- Willingness to wash out all analgesic medications used for DPNP
- Female patients either postmenopausal, surgically sterile, or practicing a medically acceptable method of contraception
- Female patients who are not pregnant

Exclusion Criteria:

- Acute infections or cardiac problems
- Past use of pregabalin
- History of severe psychiatric disorder
- History of any amputation due to diabetes
- History of seizure disorder
- Active diabetic foot ulcers

For more information:

CNS Healthcare
207 W. Gore St. Suite 200
Orlando, FL 32806
Tel: (407) 425-5100 or TOLL FREE: 1-(877) 926-5100
E-mail: Orlando@cnshealthcare.com